Pharma BD Deal Intelligence
Sobi buys into a first-in-class KIR3DL2 antibody at the confirmatory-trial stage
Full analysis, sources & comparables →Sobi and Innate Pharma entered a strategic partnership under which Sobi licenses lacutamab, an anti-KIR3DL2 monoclonal antibody, in T-cell lymphoma. Sobi pays Innate USD 75 million on closing, with up to a further USD 40 million in near-term development milestones tied to Sezary syndrome and up to USD 465 million linked to Sobi's option for full development rights plus future regulatory and commercial milestones, for a headline value of up to USD 580 million, alongside tiered double-digit royalties on net sales. Innate will run the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma supporting a planned accelerated approval filing in Sezary syndrome; Sobi receives exclusive global commercialization rights upon potential accelerated approval and may assume full global development rights after positive Phase 3 results.
Sezary syndrome is a rare, aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) characterised by erythroderma, lymphadenopathy and circulating malignant T cells. Treatment options after front-line therapy are limited and no agent is approved specifically on a KIR3DL2-directed mechanism, which is the basis for lacutamab's accelerated approval path.
Sobi gains exclusive global commercialization rights to lacutamab on potential accelerated approval while Innate retains execution risk for the TELLOMAK-3 confirmatory Phase 3. The structure - $75M on closing against up to $505M in staged milestones - keeps Sobi's committed capital small relative to headline value and defers the full development commitment to an option exercisable after Phase 3 data.
Sobi buys into a first-in-class KIR3DL2 antibody at the confirmatory-trial stage
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Innate Pharma SA (this deal) | 2026 | $580M | 68 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |